No Data
No Data
Press Release: CRISPR Therapeutics Proposes New Appointment to the Board of Directors
BofA Securities Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Cuts Target Price to $85
Crispr Therapeutics Price Target Lowered to $85 From $98 at BofA
CRISPR Therapeutics AG's (NASDAQ:CRSP) Recent 4.5% Pullback Adds to One-year Year Losses, Institutional Owners May Take Drastic Measures
CRISPR Therapeutics AG (CRSP): Is This Gene Therapy Stock a Good Buy Right Now?
Cathie Wood's ARK Investment Bought 58K Shares of Crispr Therapeutics Today
吸猫西施 : Don't worry, Sister Wood blesses you.